Neurochemical fingerprinting of the Alzheimers disease continuum using 7 T short-echo-time brain single voxel…

Abstract

IntroductionThis study aimed to characterize the neurochemical profile of Alzheimers disease (AD) continuum stages using proton magnetic resonance spectroscopy (1H-MRS) data for brain metabolites and macromolecules. We used Orthogonal Projection to Latent Structures Discriminant Analysis (OPLS-DA) to classify diagnostic groups and assess feature importance.

MethodsOur dataset consisted of 7 T short-echo time 1H-MRS spectra of the posterior cingulate cortex/precuneus of individuals diagnosed with AD (n = 27) or Mild Cognitive Impairment (MCI, n = 27) and Healthy Controls (HC, n = 31). Classification used 100-round Monte Carlo cross-validation based on metabolite concentrations and macromolecular peak intensities. Variable importance in projection (VIP) was assessed across classification models to identify the most relevant neurochemical features. The resulting metabolite rankings were compared with previous literature to evaluate their biological plausibility.

ResultsClassification was strongest for AD versus HC (AUC=0.88) and lower for comparisons involving MCI. Metabolites contributing most strongly to classification included myo-inositol, ascorbate, and choline-containing compounds, consistent with previous studies on AD-related neurochemical alterations. In addition, specific macromolecular components were identified as relevant features, suggesting a potential contribution of MM signals to the characterization of AD-related neurochemistry.

DiscussionThese findings support the use of short-echo-time 1H-MRS as a complementary tool for characterizing neurochemical changes in the AD continuum, with potential applications in disease characterization and monitoring, warranting validation in larger cohorts.

Discovery of a brain-penetrant CHI3L1 inhibitor as an oral modulator of neuroinflammation in Alzheimers disease
S. Upadhyay, L. Zhang, B. Kaur +3
bioRxiv15 Oct 2026PreprintAll rights reservedFull textPharmacology & toxicologybioRxivPMC
Proteomic markers linking anxiety phenotypes to Alzheimers disease risk: a multi-analyte proteomic analysis
A. P. Costa, H. T. Karim, M. F. Farinas +6
medRxiv16 Sep 2026PreprintAll rights reservedFull text1 citedPsychiatry & mental healthmedRxiv
Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims
A. Tiwari, R. Chen, Y. Tan +5
medRxiv11 Sep 2026PreprintAll rights reservedFull textNeurologymedRxiv
Memory Self-Awareness Phenotypes are Associated with Alzheimers Disease Biomarker Burden and Clinical Progression in Amnestic Mild Cognitive Impairment
N. Enbar-Salo, P. Palmer, C. Munro +7
medRxiv3 Nov 2026PreprintCC BY-NC-NDFull textNeurologymedRxiv
Alzheimers disease blood biomarkers reveal proteomic modules of disease progression
Robert R. Butler, Michael P. Brown, Audrey J. Weber +13
medRxiv14 Aug 2026PreprintCC BY-NCFull textNeurologymedRxivPMC

Cite

BibTeX RIS

BibTeX

@misc{dellorco2026neurochemical,
  title = {{Neurochemical fingerprinting of the Alzheimers disease continuum using 7 T short-echo-time brain single voxel 1H-MRS.}},
  author = {A. Dell'Orco and L. Göschel and L. T. Riemann and S. Aydin and A. Flöel and A. Tietze and M. Scheel and A. Fillmer},
  howpublished = {medRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.16.26365733},
  url = {https://www.medrxiv.org/content/10.64898/2026.10.16.26365733v1},
  note = {CC BY},
}

RIS

TY  - UNPB
TI  - Neurochemical fingerprinting of the Alzheimers disease continuum using 7 T short-echo-time brain single voxel 1H-MRS.
AU  - A. Dell'Orco
AU  - L. Göschel
AU  - L. T. Riemann
AU  - S. Aydin
AU  - A. Flöel
AU  - A. Tietze
AU  - M. Scheel
AU  - A. Fillmer
PY  - 2026
DA  - 2026/10/16
PB  - medRxiv
DO  - 10.64898/2026.10.16.26365733
UR  - https://www.medrxiv.org/content/10.64898/2026.10.16.26365733v1
AB  - IntroductionThis study aimed to characterize the neurochemical profile of Alzheimers disease (AD) continuum stages using proton magnetic resonance spectroscopy (1H-MRS) data for brain metabolites and macromolecules. We used Orthogonal Projection to Latent Structures Discriminant Analysis (OPLS-DA) to classify diagnostic groups and assess feature importance.  MethodsOur dataset consisted of 7 T short-echo time 1H-MRS spectra of the posterior cingulate cortex/precuneus of individuals diagnosed with AD (n = 27) or Mild Cognitive Impairment (MCI, n = 27) and Healthy Controls (HC, n = 31). Classification used 100-round Monte Carlo cross-validation based on metabolite concentrations and macromolecular peak intensities. Variable importance in projection (VIP) was assessed across classification models to identify the most relevant neurochemical features. The resulting metabolite rankings were compared with previous literature to evaluate their biological plausibility.  ResultsClassification was strongest for AD versus HC (AUC=0.88) and lower for comparisons involving MCI. Metabolites contributing most strongly to classification included myo-inositol, ascorbate, and choline-containing compounds, consistent with previous studies on AD-related neurochemical alterations. In addition, specific macromolecular components were identified as relevant features, suggesting a potential contribution of MM signals to the characterization of AD-related neurochemistry.  DiscussionThese findings support the use of short-echo-time 1H-MRS as a complementary tool for characterizing neurochemical changes in the AD continuum, with potential applications in disease characterization and monitoring, warranting validation in larger cohorts.
ER  -

Abstract

Related

Cite